NASDAQ:TLSA Tiziana Life Sciences - TLSA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Tiziana Life Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. $0.65 0.00 (0.00%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.60▼$0.6550-Day Range$0.56▼$0.6752-Week Range$0.53▼$1.38Volume45,286 shsAverage Volume47,671 shsMarket Capitalization$66.20 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Tiziana Life Sciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside518.0% Upside$4.00 Price TargetShort InterestHealthy0.06% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.62Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.37) to ($0.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.05 out of 5 starsMedical Sector621st out of 1,055 stocksPharmaceutical Preparations Industry314th out of 519 stocks 3.5 Analyst's Opinion Consensus RatingTiziana Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Tiziana Life Sciences has a forecasted upside of 518.0% from its current price of $0.65.Amount of Analyst CoverageTiziana Life Sciences has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.06% of the outstanding shares of Tiziana Life Sciences have been sold short.Short Interest Ratio / Days to CoverTiziana Life Sciences has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tiziana Life Sciences has recently increased by 15.55%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTiziana Life Sciences does not currently pay a dividend.Dividend GrowthTiziana Life Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TLSA. Previous Next 2.0 News and Social Media Coverage News SentimentTiziana Life Sciences has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Tiziana Life Sciences this week, compared to 1 article on an average week.Search InterestOnly 7 people have searched for TLSA on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tiziana Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders39.82% of the stock of Tiziana Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 5.21% of the stock of Tiziana Life Sciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Tiziana Life Sciences are expected to grow in the coming year, from ($0.37) to ($0.32) per share.Price to Book Value per Share RatioTiziana Life Sciences has a P/B Ratio of 1.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Tiziana Life Sciences (NASDAQ:TLSA) StockTiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.Read More Receive TLSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tiziana Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address TLSA Stock News HeadlinesJanuary 21, 2023 | americanbankingnews.comTiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest UpdateJanuary 4, 2023 | proactiveinvestors.comTiziana Life Sciences says IND filed for Phase 2 study of milciclib in combination with gemcitabine for non-small cell lung cancerJanuary 28, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 4, 2023 | finance.yahoo.comTiziana Life Sciences Announces IND filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung CancerJanuary 3, 2023 | finance.yahoo.comTiziana Life Sciences Posts Additional Clinical Improvements In Second Patient with Multiple SclerosisJanuary 3, 2023 | proactiveinvestors.comTiziana Life Sciences hails more improvements in MS patient after 11 months dosing with intranasal foralumabJanuary 3, 2023 | tmcnet.comTiziana Life Sciences Announces Additional Clinical Improvements inJanuary 3, 2023 | finance.yahoo.comTiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal ForalumabJanuary 28, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.December 29, 2022 | finance.yahoo.comTiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Updated Interim Results for the Six Months Ended 30 June 2022December 28, 2022 | proactiveinvestors.comTiziana Life Sciences ups R&D spend in first half of 2022 as it advances its next-generation therapeuticsDecember 27, 2022 | finance.yahoo.comTiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Interim Results for the Six Months Ended 30 June 2022December 16, 2022 | finanznachrichten.deTiziana Life Sciences Ltd.: Tiziana to Participate in January Investor MeetingsDecember 16, 2022 | finance.yahoo.comTiziana to Participate in January Investor MeetingsDecember 15, 2022 | finanznachrichten.deTiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety StudyDecember 15, 2022 | proactiveinvestors.comTiziana Life Sciences reveals successful completion of intranasal foralumab pre-clinical safety studyDecember 15, 2022 | finance.yahoo.comTiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety StudyDecember 14, 2022 | finance.yahoo.comTiziana Life Sciences Ltd. Granted 180-day Extension by Nasdaq to Meet Minimum Bid Price RequirementsDecember 6, 2022 | finance.yahoo.comTiziana Life Sciences Announces Date of Annual General Meeting 2022December 5, 2022 | finance.yahoo.comTLSA: November’s Investor DayNovember 23, 2022 | finance.yahoo.comTiziana Announces Publication of a Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell Function and an Induced T Cell Regulatory Response in Human SubjectsNovember 10, 2022 | finance.yahoo.comTiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS)November 4, 2022 | proactiveinvestors.comTiziana Life Sciences under the eye of Proactive research analyst John SavinNovember 4, 2022 | finance.yahoo.comTiziana Life Sciences to Host Investor CallNovember 2, 2022 | proactiveinvestors.comTiziana finishes enrolling first patient cohort for expanded access program evaluating Foralumab in advanced stage multiple sclerosisNovember 2, 2022 | finance.yahoo.comTiziana Life Sciences Completes Enrollment of the First Patient Cohort for its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis PatientsOctober 27, 2022 | proactiveinvestors.comTiziana Life Sciences starts enrollment of first patient cohort in... Tiziana Life Sciences starts enrollment of first patient cohort in...See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TLSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tiziana Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address TLSA Company Calendar Today1/28/2023Next Earnings (Estimated)5/19/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TLSA CUSIPN/A CIK1723069 Webwww.tizianalifesciences.com Phone44-20-7495-2379FaxN/AEmployees11Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.00 High Stock Price Forecast$4.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+518.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio6.12 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.40 per share Price / Book1.62Miscellaneous Outstanding Shares102,270,000Free Float61,548,000Market Cap$66.20 million OptionableNot Optionable Beta0.82 Key ExecutivesMr. Gabriele Marco Antonio Cerrone M.B.A. (Age 50)MBA, Founder, Exec. Chairman & Interim CEO Comp: $1.19MDr. Andrea BrancaleScientific FounderMr. Richard Clarkson Ph.D.Scientific FounderMr. Andrew Westwell Ph.D.Scientific FounderMs. Keeren Shah (Age 45)Chief Financial Officer Dr. Matthew W. Davis M.D.RPh, Chief Medical Officer & Acting Chief Scientific OfficerProf. Napoleone Ferrara M.D. (Age 65)Member of Scientific Advisory Board Prof. Roberto Pellicciari Ph.D.ConsultantMore ExecutivesKey CompetitorsTonix PharmaceuticalsNASDAQ:TNXPConnect BiopharmaNASDAQ:CNTBSpruce BiosciencesNASDAQ:SPRBGalectin TherapeuticsNASDAQ:GALTOncternal TherapeuticsNASDAQ:ONCTView All CompetitorsInsiders & InstitutionsState Street CorpSold 104,442 shares on 11/15/2022Ownership: 0.213%Cantor Fitzgerald L. P.Bought 45,991 shares on 11/15/2022Ownership: 0.045%View All Institutional Transactions TLSA Stock - Frequently Asked Questions Should I buy or sell Tiziana Life Sciences stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tiziana Life Sciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TLSA shares. View TLSA analyst ratings or view top-rated stocks. What is Tiziana Life Sciences' stock price forecast for 2023? 1 Wall Street analysts have issued 12-month price targets for Tiziana Life Sciences' stock. Their TLSA share price forecasts range from $4.00 to $4.00. On average, they expect the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 518.0% from the stock's current price. View analysts price targets for TLSA or view top-rated stocks among Wall Street analysts. How have TLSA shares performed in 2023? Tiziana Life Sciences' stock was trading at $0.5985 on January 1st, 2023. Since then, TLSA stock has increased by 8.2% and is now trading at $0.6473. View the best growth stocks for 2023 here. Are investors shorting Tiziana Life Sciences? Tiziana Life Sciences saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 65,400 shares, an increase of 15.5% from the December 31st total of 56,600 shares. Based on an average daily volume of 53,300 shares, the short-interest ratio is currently 1.2 days. View Tiziana Life Sciences' Short Interest. When is Tiziana Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 19th 2023. View our TLSA earnings forecast. What other stocks do shareholders of Tiziana Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tiziana Life Sciences investors own include Pfizer (PFE), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Moderna (MRNA), Enterprise Products Partners (EPD), Novavax (NVAX), Dynavax Technologies (DVAX) and Gilead Sciences (GILD). When did Tiziana Life Sciences IPO? (TLSA) raised $10 million in an initial public offering (IPO) on the week of November 19th 2018. The company issued 1,000,000 shares at a price of $9.90 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO. What is Tiziana Life Sciences' stock symbol? Tiziana Life Sciences trades on the NASDAQ under the ticker symbol "TLSA." How do I buy shares of Tiziana Life Sciences? Shares of TLSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Tiziana Life Sciences' stock price today? One share of TLSA stock can currently be purchased for approximately $0.65. How much money does Tiziana Life Sciences make? Tiziana Life Sciences (NASDAQ:TLSA) has a market capitalization of $66.20 million. How can I contact Tiziana Life Sciences? Tiziana Life Sciences' mailing address is 3RD FLOOR 11-12 ST. JAMES`S SQUARE, LONDON X0, SW1Y 4LB. The official website for the company is www.tizianalifesciences.com. The company can be reached via phone at 44-20-7495-2379 or via email at info@tizianalifesciences.com. This page (NASDAQ:TLSA) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.